Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work with Us
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work with Us
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Search type
Keyword
Author
Edition
European
US
Urology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Interviews
Podcasts
Videos & Webinars
News
Infographics
Society updates
Submit A Paper
Renal Cell Carcinoma Brain Metastases Survival Improves
November 2026
Survival improved among patients with renal cell carcinoma and brain metastases, while the updated Renal GPA stratified outcomes from 4.8 to 51.2 months.
Read more
17 Nov 2026
Renal Cell Carcinoma Brain Metastases Survival Improves
Survival improved among patients with renal cell carcinoma and brain metastases, while the updated Renal GPA stratified outcomes from 4.8 to 51.2 months.
14 Nov 2026
Overactive Bladder Drugs Show No Dementia Risk Advantage
A study of 830,393 adults found that β3 agonists were not associated with lower dementia incidence than anticholinergic medications for overactive bladder. Longer anticholinergic exposure was not linked to increased risk.
12 Nov 2026
Diet and Dosimetry Linked to Cystitis After Prostate Radiotherapy
A multicentre study identified bladder radiation exposure, antithrombotic use and dietary inflammation as factors associated with late radiation cystitis.
10 Nov 2026
Segmental Resection Improves Upper Tract Urothelial Cancer Survival
A matched cohort study of 312 patients with upper tract urothelial carcinoma found that segmental resection was associated with improved overall and cancer-specific survival compared with local tumour excision.
7 Nov 2026
Androgen Receptor Inhibitors Linked to Longer mHSPC Survival
A cohort study found longer overall survival with androgen receptor inhibitors than androgen synthesis inhibitors among patients with metastatic hormone-sensitive prostate cancer.
5 Nov 2026
Local Treatment Linked to Longer Survival in Prostate Cancer
Local treatment was linked to fewer years of life lost in intermediate-risk prostate cancer, particularly among younger patients.
3 Nov 2026
Kidney Stone Prevention Knowledge Gaps Identified in Sudan
Kidney stone prevention knowledge gaps were identified among 405 Sudanese healthcare providers.
31 Oct 2026
Denosumab Duration Linked to Jaw Necrosis Risk in Prostate Cancer
A nationwide cohort study found that longer denosumab treatment was associated with increased osteonecrosis of the jaw risk but no additional reduction in skeletal events beyond 12 months.
Loading posts...
1
2
3
…
58
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View